Results 11 to 20 of about 425,993 (391)

HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe [PDF]

HIV Medicine, 2021
AbstractObjectivesAlthough direct‐acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV‐coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV‐coinfected individuals in Europe.MethodsFactors associated with odds of
Amele S., Sandri A. K., Rodger A., Vandekerckhove L., Benfield T., Milinkovic A., Duvivier C., Stellbrink H. -J., Sambatakou H., Chkhartishvili N., Caldeira L., Laguno M., Domingo P., Wandeler G., Gisinger M., Kuzovatova E., Dragovic G., Knysz B., Matulionyte R., Rockstroh J. K., Lundgren J. D., Mocroft A., Peters L., Harxhi A., Losso M., Kundro M., Schmied B., Zangerle R., Karpov I., Vassilenko A., Mitsura V. M., Paduto D., Clumeck N., Wit S. D., Delforge M., Florence E., Vandekerckhove L., Hadziosmanovic V., Begovac J., Machala L., Jilich D., Sedlacek D., Kronborg G., Benfield T., Gerstoft J., Katzenstein T., Pedersen C., Johansen I. S., Ostergaard L., Wiese L., Moller N. F., Nielsen L. N., Zilmer K., Smidt J., Aho I., Viard J. -P., Girard P. -M., Pradier C., Fontas E., Duvivier C., Rockstroh J., Behrens G., Degen O., Stellbrink H. J., Stefan C., Bogner J., Fatkenheuer G., Chkhartishvili N., Sambatakou H., Adamis G., Paissios N., Szlavik J., Gottfredsson M., Devitt E., Tau L., Turner D., Burke M., Shahar E., Hassoun G., Elinav H., Haouzi M., Elbirt D., D'Arminio Monforte A., Esposito R., Mazeu I., Mussini C., Mazzotta F., Gabbuti A., Lazzarin A., Castagna A., Gianotti N., Galli M., Ridolfo A., Sacco L., Uzdaviniene V., Matulionyte R., Staub T., Hemmer R., Dragas S., Stevanovic M., Reiss P., Trajanovska J., Reikvam D. H., Maeland A., Bruun J., Knysz B., Gasiorowski J., Inglot M., Bakowska E., Flisiak R., Grzeszczuk A., Parczewski M., Maciejewska K., Aksak-Was B., Beniowski M., Mularska E., Jablonowska E., Kamerys J., Wojcik K., Mozer-Lisewska I., Rozplochowski B., Zagalo A., Mansinho K., Maltez F., Radoi R., Oprea C., Davila C., Yakovlev A., Trofimora T., Khromova I., Kuzovatova E., Blokhina I. N., Novogrod N., Borodulina E., Vdoushkina E., Ranin J., Tomazic J., Miro J. M., Miro J. M., Martinez E., Garcia F., Blanco J. L., Martinez-Rebollar M., Mallolas J., Callau P., Rojas J., Inciarta A., Moreno S., del Campo S., Clotet B., Jou A., Paredes R., Puig J., Llibre J. M., Santos J. R., Domingo P., Gutierrez M., Mateo G., Sambeat M. A., Laporte J. M., Falconer K., Thalme A., Sonnerborg A., Brannstrom J., Flamholc L., Scherrer A., Weber R., Cavassini M., Calmy A., Furrer H., Battegay M., Schmid P., Kuznetsova A., Mikhalik J., Sluzhynska M., Milinkovic A., Johnson A. M., Simons E., Edwards S., Phillips A., Johnson M. A., Mocroft A., Orkin C., Winston A., Clarke A., Leen C., Karpov I., Losso M., Lundgren J., Rockstroh J., Aho I., Rasmussen L. D., Svedhem V., Wandeler G., Pradier C., Chkhartishvili N., Matulionyte R., Oprea C., Kowalska J. D., Begovac J.   +199 more
openaire   +7 more sources

Screening for HCV [PDF]

Canadian Medical Association Journal, 2014
We applaud Shah and colleagues[1][1] for raising the issue of establishing a Canadian screening program for hepatitis C. We agree that hepatitis C shows the hallmarks of an infectious disease suited to a screening program,[2][2] but we are concerned that the extrapolation of American data into ...
Aaron Orkin, Kathleen Dooling, Fiona G. Kouyoumdjian, Michael Schwandt   +3 more
openaire   +7 more sources

HCV and Lymphoproliferation [PDF]

Clinical and Developmental Immunology, 2012
Hepatitis C virus (HCV) infection is a serious public health problem because of its worldwide diffusion and sequelae. It is not only a hepatotropic but also a lymphotropic agent and is responsible not only for liver injury—potentially evolving to cirrhosis and hepatocellular carcinoma—but also for a series of sometimes severely disabling extrahepatic ...
ZIGNEGO, ANNA LINDA, GIANNINI, CARLO, GRAGNANI, LAURA   +2 more
openaire   +7 more sources

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes [PDF]

BMC Infectious Diseases, 2014
A good correlation between HCV core antigen (HCVAg) and different HCV-RNA assays has been described, but little data are available in HCV/HIV co-infection. We aimed to evaluate HCVAg in comparison with HCV-RNA and to determine their kinetics during antiviral treatment in selected HCV/HIV co-infected patients.355 samples from 286 HCV/HIV co-infected ...
Anna Rosa Garbuglia, Maria Rosaria Capobianchi, Claudio Galli, Patrizia Bagnarelli, Monica Lucia Ferreri, Alessia Monachetti, Rosella Sabatini   +6 more
openaire   +3 more sources

HCV and the kidney [PDF]

Liver International, 2016
AbstractChronic hepatitis C (CHC) is significantly associated with a risk of renal deterioration over time. Renal impairment, especially stage 4–5 chronic kidney disease, increases the risk of: (i) the prevalence and incidence (in dialysis/transplantation) of hepatitis C virus (HCV) infection; (ii) liver deterioration during kidney transplantation and (
Anaïs Vallet-Pichard, Anaïs Vallet-Pichard, Stanislas Pol, Stanislas Pol, Marion Corouge, Marion Corouge   +5 more
openaire   +3 more sources

HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV‐Associated Pathogenesis [PDF]

Oxidative Medicine and Cellular Longevity, 2016
HCV (hepatitis C virus) is a member of the Flaviviridae family that contains a single‐stranded positive‐sense RNA genome of approximately 9600 bases. HCV is a major causative agent for chronic liver diseases such as steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma which are caused by multifactorial processes.
Regina Medvedev, Eberhard Hildt, Daniela Ploen   +2 more
openaire   +2 more sources

Comparison of HCV core antigen and anti-HCV with HCV RNA results

African Health Sciences, 2015
The measurement of anti-HCV antibodies using immunological methods and the confirmation of viral nuclear acid based on molecular methods is important in diagnosis and follow-up of the HCV infection.In this study, we aimed to analyse HCV core Antigen positivity among anti-HCV antibody positive sera to determine the significance of testing of HCV core Ag
Ayse, Aynali, Emel, Sesli Cetin, Sueleyman, Oenal, Selcuk, Kaya, Buket, Cicioglu Aridogan   +4 more
openaire   +7 more sources

Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV† [PDF]

Hepatology, 2004
Persons with human immunodeficiency virus (HIV) and hepatits C virus (HCV) coinfection are at increased risk for progression to cirrhosis compared with persons with HCV alone, but the reasons for this are unclear. In chronic HCV, the mechanism of liver injury is presumed to be due to HCV-specific T cell destruction of ...
Nezam H. Afdhal, Donald E. Craven, Michael P. Curry, Robert Horsburgh, Catherine A. Fleming, David Nunes, Camilla S. Graham, Qi He, Kenneth E. Sherman, Margaret James Koziel   +9 more
openaire   +3 more sources

Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. [PDF]

, 2006
In the past several years, a number of cellular proteins have been identified as candidate entry receptors for hepatitis C virus (HCV) by using surrogate models of HCV infection.
Barth, Heidi, Baumert, Thomas, Chisari, Francis V, Kapadia, Sharookh B, McKeating, Jane A   +4 more
core   +2 more sources

Sox4 represses host innate immunity to facilitate pathogen infection by hijacking the TLR signaling networks

Virulence, 2021
Toll-like receptors (TLRs) are essential for the protection of the host from pathogen infections by initiating the integration of contextual cues to regulate inflammation and immunity.
Jian Shang, Yuan Zheng, Jiayin Mo, Wenbiao Wang, Zhen Luo, Yongkui Li, Xulin Chen, Qiwei Zhang, Kailang Wu, Weiyong Liu, Jianguo Wu   +10 more
doaj   +1 more source